Dear readers,
Download this report to explore pioneering advancements in antibody-based therapies that target immune pathways to combat challenging diseases. Søren Bregenholt, CEO of Alligator Bioscience, shares insights on a bispecific antibody approach targeting CD40 to enhance immune response against tumors, with promising applications in pancreatic cancer treatment. Additionally, Dr. Judy Chou, CEO of AltruBio, Inc., discusses how agonist antibodies could reshape therapies for immunological diseases by modulating immune cell interactions to manage inflammation effectively.
Other articles inside include:
Combining precision bispecific antibodies with targeted radiotherapy by Alexander Schinagl, co-founder and Chief Technology Officer of OncoOne
Radioimmunotherapy (RIT) is a promising cancer treatment gaining recognition in precision oncology. It utilises radiolabelled antibodies to deliver targeted radiation to tumours, with success in haematologic cancers. However, its use in solid tumours has been limited by off-target radiation and toxicity, with few clinical trials advancing beyond phase II.
Detecting antibodies unique to stage I and II melanoma patients by Ellen Capon at Drug Target Review
A new method, using tumour-specific profiling to detect antibodies unique to stage I and II melanoma patients, was presented1 at the European Academy of Dermatology and Venerology (EADV) Congress 2024, which could greatly improve both diagnosis and prognosis.
Promising effect of anti-CADM1 antibody on neuronal activity by Ellen Capon at Drug Target Review
Researchers at Kindai University in Japan investigated the effect of anti-CADM1 antibodies on neuronal activity, with their findings likely to open a new field of long-acting analgesics, offering hope for a safer pain-relieving strategy.
